Britain and America have finalized a landmark bilateral deal that will ensure no import taxes on British drug shipments entering the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to boost spending on pharmaceuticals through the National Health Service (NHS). This move guarantees that duties on these crucial exports will be held at zero for a timeframe of the next three years.
This deal is in response to previous threats to hike duties on patented drug products, with potential rates mentioned up to 100%.
"This deal with the United Kingdom bolsters the international landscape for innovative medicines and establishes long-overdue fairness to transatlantic drug exports," a release declared.
Economic Importance
Drugs constitute one of the Britain's most significant export categories to the America, which is clearly the largest destination for major UK drugmakers.
Statistics show that in the 12 months to the end of last September, the UK sold medicines valued at billions to the US. This amount represented a significant portion of all goods exports in that span.
"This agreement protects work, boosts capital expenditure and sets the stage for the UK to become a international leader for medical research," a government official remarked.
Specific UK Commitments
The deal includes several key pledges from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to prevent overspending will be limited at 15%. Last year, repayments topped 20%.
Broader Context
The pact follows a long-running tension between the drug companies and the British authorities over drug pricing and approval rates.
This friction were heightened by arguments that American consumers were paying significantly more for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while substantial expansions have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the past decade.
